MA49607B2 - ANTICORPS MONOCLONAL POUR IL-5Rα - Google Patents

ANTICORPS MONOCLONAL POUR IL-5Rα

Info

Publication number
MA49607B2
MA49607B2 MA49607A MA49607A MA49607B2 MA 49607 B2 MA49607 B2 MA 49607B2 MA 49607 A MA49607 A MA 49607A MA 49607 A MA49607 A MA 49607A MA 49607 B2 MA49607 B2 MA 49607B2
Authority
MA
Morocco
Prior art keywords
monoclonal antibody
antibodies
methods
relates
dnas
Prior art date
Application number
MA49607A
Other languages
English (en)
Other versions
MA49607A1 (fr
Inventor
Valery Vladimirovich SOLOVYEV
Dmitry Valentinovich MOROZOV
Ekaterina Vladimirovna SOFRONOVA
Aleksei Konstantinovich MISORIN
Aleksandr Nikolaevich Doronin
Timofey Aleksandrovich Nemankin
Aleksandra Aleksandrovna SOZONOVA
Galina Stepanovna Zhirivskala
Sergey Aleksandrovich LEGOTSKY
Anna Konstantinovna VLADIMIROVA
Alina Valerevna BELIASNIKOVA
Mariia Aleksandrovna SHCHEMELEVA
Pavel Andreevich IAKOVLEV
Elena Andreevna KRENDELEVA
Natalia Evgenevna PESTOVA
Original Assignee
Joint Stock Company "Biocad"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Stock Company "Biocad" filed Critical Joint Stock Company "Biocad"
Publication of MA49607A1 publication Critical patent/MA49607A1/fr
Publication of MA49607B2 publication Critical patent/MA49607B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne le domaine de la biotechnologie et propose des anticorps qui se lient spécifiquement à IL-5Rα. L'invention concerne des ADN qui codent pour lesdits anticorps, qui correspondent aux vecteurs d'expression, et des procédés de production ainsi que des méthodes de traitement utilisant ces anticorps.
MA49607A 2017-10-03 2018-10-02 ANTICORPS MONOCLONAL POUR IL-5Rα MA49607B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017134413A RU2698048C2 (ru) 2017-10-03 2017-10-03 МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
PCT/RU2018/050118 WO2019070164A1 (fr) 2017-10-03 2018-10-02 ANTICORPS MONOCLONAL POUR IL-5Rα

Publications (2)

Publication Number Publication Date
MA49607A1 MA49607A1 (fr) 2021-03-31
MA49607B2 true MA49607B2 (fr) 2024-11-29

Family

ID=65994565

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49607A MA49607B2 (fr) 2017-10-03 2018-10-02 ANTICORPS MONOCLONAL POUR IL-5Rα

Country Status (23)

Country Link
US (1) US12173075B2 (fr)
EP (1) EP3693388A4 (fr)
JP (1) JP7275117B2 (fr)
KR (1) KR102749809B1 (fr)
CN (1) CN111788223B (fr)
AR (1) AR113343A1 (fr)
AU (1) AU2018346116B2 (fr)
BR (1) BR112020006795A2 (fr)
CA (1) CA3078467A1 (fr)
CL (1) CL2020000920A1 (fr)
CO (1) CO2020004200A2 (fr)
EA (1) EA202090864A1 (fr)
EC (1) ECSP20024551A (fr)
JO (1) JOP20200106A1 (fr)
MA (1) MA49607B2 (fr)
MX (1) MX2020004026A (fr)
PE (1) PE20210466A1 (fr)
PH (1) PH12020550218A1 (fr)
RU (1) RU2698048C2 (fr)
TW (1) TWI758547B (fr)
UY (1) UY37914A (fr)
WO (1) WO2019070164A1 (fr)
ZA (1) ZA202002044B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR102697770B1 (ko) * 2020-09-14 2024-08-23 아주대학교산학협력단 인간 IL-5Rα에 결합하는 항체 및 이의 용도
US20220193238A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
EP4393907A4 (fr) * 2021-08-26 2024-11-20 Neushen Therapeutics (Shanghai) Co., Ltd Modulateur des canaux potassiques, composition et application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095765A1 (en) * 2003-10-08 2008-04-24 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
EP3060579A1 (fr) * 2013-10-25 2016-08-31 Numab AG Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (fr) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Proteine cd2 soluble a deux domaines
WO1990011294A1 (fr) 1989-03-21 1990-10-04 The Immune Response Corporation Vaccination et procedes contre des maladies resultant des reponses pathogeniques par des populations de cellules t specifiques
EP0479909B1 (fr) 1989-06-29 1996-10-30 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
DK0552142T3 (da) 1989-07-19 1998-09-07 Connetics Corp T-cellereceptorpeptider og terapeutika til autoimmune og maligne sygdomme
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
EP0656064B1 (fr) 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
FR2783326B1 (fr) 1998-09-10 2000-12-01 Immunotech Sa Procede de detection ou de quantification des basophiles et des eosinophiles
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
DE60138222D1 (de) 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
ATE435239T1 (de) * 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
AU2004279740A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
DK3072525T3 (en) 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
KR101962483B1 (ko) * 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
RU2015122228A (ru) 2012-12-12 2017-01-19 Васкулокс Инк. Терапевтические антитела к CD47
WO2015172800A1 (fr) 2014-05-12 2015-11-19 Numab Ag Nouvelles molécules multispécifiques et nouvelles méthodes de traitement basées sur ces molécules multispécifiques
LT3033101T (lt) * 2013-08-12 2019-03-25 Astrazeneca Ab Astmos paūmejimo dažnio sumažinimo būdai naudojant benralizumabą
JP6895884B2 (ja) 2015-06-01 2021-06-30 国立大学法人富山大学 肺高血圧症の治療薬及び治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095765A1 (en) * 2003-10-08 2008-04-24 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
EP3060579A1 (fr) * 2013-10-25 2016-08-31 Numab AG Constructions bispécifiques et leur utilisation dans le traitement de diverses maladies

Also Published As

Publication number Publication date
AR113343A1 (es) 2020-04-22
NZ763877A (en) 2025-05-02
US20200291121A1 (en) 2020-09-17
EA202090864A1 (ru) 2020-06-29
PH12020550218A1 (en) 2021-02-15
JOP20200106A1 (ar) 2020-05-06
JP7275117B2 (ja) 2023-05-17
CN111788223A (zh) 2020-10-16
MX2020004026A (es) 2020-08-13
PE20210466A1 (es) 2021-03-08
UY37914A (es) 2019-04-30
TWI758547B (zh) 2022-03-21
US12173075B2 (en) 2024-12-24
ECSP20024551A (es) 2020-06-30
EP3693388A4 (fr) 2021-06-23
CN111788223B (zh) 2024-08-30
CA3078467A1 (fr) 2019-04-11
CL2020000920A1 (es) 2020-10-16
AU2018346116A1 (en) 2020-05-14
BR112020006795A2 (pt) 2020-10-06
RU2017134413A3 (fr) 2019-04-03
WO2019070164A1 (fr) 2019-04-11
EP3693388A1 (fr) 2020-08-12
ZA202002044B (en) 2022-08-31
AU2018346116B2 (en) 2025-10-09
KR102749809B1 (ko) 2025-01-03
RU2017134413A (ru) 2019-04-03
MA49607A1 (fr) 2021-03-31
JP2021501568A (ja) 2021-01-21
TW201922789A (zh) 2019-06-16
KR20200058537A (ko) 2020-05-27
RU2698048C2 (ru) 2019-08-21
CO2020004200A2 (es) 2020-04-24

Similar Documents

Publication Publication Date Title
MA47221A1 (fr) Anticorps monoclonal à pd-l1
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
MA49034B1 (fr) Anticorps anti-lag3
JOP20200157A1 (ar) أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ cd22
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
EA201992038A1 (ru) Анти-псф-тау-антитела и способы их применения
JOP20220119A1 (ar) أجسام مضادة trem2 واستخداماتها
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA201892440A1 (ru) Антитела к tl1a и их применения
MA41596A (fr) Anticorps anti-tau et leurs utilisations
MA49607A1 (fr) Anticorps monoclonal pour il-5ra
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MA38161A1 (fr) Anticorps anti-bmp-6
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
MA53186A1 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
MA43600B2 (fr) Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire
GEP20247700B (en) Antibody variants
EA201891196A1 (ru) Cgrp-антитела и их применение
EA202090929A1 (ru) Антитела, активируемые антитела, биспецифические антитела и биспецифические активируемые антитела и способы их применения
EA202092981A1 (ru) Антитела к l1cam и их применение
MA39300A1 (fr) Anticorps bispécifiques anti-il-13/il-17 et leurs utilisations
MA41930A1 (fr) Composition pour traitement de la maladie du bayoud
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения